Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab

被引：0
|
作者：
Reck, Martin
Granados, Ana Laura Ortega
de Marinis, Filippo
Meyers, Oren
Boklage, Susan
Shen, Qin
Cho, Lillian
机构：
[1] Lungen Clin, Grosshansdorf, Germany
[2] Hosp Univ Jaen, Serv Oncol Med, Jaen, Spain
[3] European Inst Oncol, Milan, Italy
[4] GSK, Collegeville, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
芬兰科学院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9099
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China
    Yang, Zhiguang
    Zhu, Yumei
    Xiang, Guiyuan
    Hua, Tiantian
    Ni, Jun
    Zhao, Jie
    Lu, Yun
    Wu, Yingyu
    Chang, Feng
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (05) : 1061 - 1067
  • [22] Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer
    Xu, Haiyan
    Xu, Fei
    Zhu, Wenjie
    Ying, Jianming
    Wang, Yan
    THORACIC CANCER, 2018, 9 (08) : 1005 - 1011
  • [23] The potential cost-effectiveness of first-line immunotherapy plus chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC).
    Roth, Joshua A.
    Trung Nguyen
    Goulart, Bernardo H. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non-small-cell lung cancer in China
    Jiang, Yuan
    Wang, Xingwei
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2022, 29 (03) : 139 - 144
  • [25] Prognostic Factors in the First-Line Chemotherapy of Advanced Non-Squamous Non-Small Cell Lung Cancer Patients with Performance Status 2
    Hosokawa, Shinobu
    Bessho, Akihiro
    Nishii, Kazuya
    Fukamatsu, Nobuaki
    Ogata, Yoshiko
    Sakugawa, Makoto
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S418 - S418
  • [26] FDG-PET/CT to predict outcome of first-line chemotherapy plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer
    Usmanij, Edwin
    Natroshvili, Tinatin
    Timmer-Bonte, Johanna
    van der Drift, Miep
    Oyen, Wim
    Bussink, Johan
    De Geus-Oei, Lioe-Fee
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [27] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB PLUS IPILIMUMAB VS. PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF NON-SQUAMOUS, ADVANCED NON-SMALL CELL LUNG CANCER IN THE USA
    Chen, J.
    Velcheti, V.
    Padula, W.
    VALUE IN HEALTH, 2022, 25 (07) : S342 - S342
  • [28] Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer
    Peravali, Monica
    Ahn, Jaeil
    Chen, Kevin
    Rao, Suman
    Veytsman, Irina
    Liu, Stephen V.
    Kim, Chul
    ONCOLOGIST, 2021, 26 (08): : 694 - 700
  • [29] Pembrolizumab for the first-line treatment of non-small cell lung cancer
    Ninomiya, Kiichiro
    Hotta, Katsuyuki
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (10) : 1015 - 1021
  • [30] Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer
    Losanno, Tania
    Gridelli, Cesare
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (06) : 837 - 851
12345